文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌近距离放疗中环形与卵形施用器及腔内与腔内-组织间插植技术的比较:EMBRACE I研究结果

Ring Versus Ovoids and Intracavitary Versus Intracavitary-Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-30

结果显示环形-腔内中心靶区D90%更高、V85Gy更低,膀胱和直肠剂量更小,但阴道5mm侧点剂量更高;常规使用腔内/组织间插植技术可改善靶区覆盖并降低部分危及器官剂量。

要点

  • 环形-腔内施用器较卵形-腔内靶区剂量更高、适形性更好且膀胱直肠剂量更低。
  • 腔内施用器难以覆盖大靶区,常规腔内/组织间插植可显著改善靶区和危及器官剂量。
  • 环形施用器在靶区、膀胱直肠剂量和V85Gy上治疗比更有利,但阴道5mm侧点剂量更高。

核心结论

  • 在本代表性队列中,串联-环形-腔内施用器较串联-卵形-腔内具有更好的靶区剂量和剂量适形性。
  • 腔内施用器无法覆盖大靶区,而常规应用腔内/组织间插植技术可显著改善靶区和危及器官剂量。
  • 评估靶区、膀胱直肠剂量和V85Gy时,串联-环形治疗患者显示更有利的治疗比。

研究设计与样本

  • 患者接受外照射和磁共振引导近距离放疗,剂量处方按各中心实践。
  • 按施用器/技术将中心分为4组:卵形和环形中心分别主要使用腔内技术或常规使用腔内/组织间插植技术。
  • 评估指标包括V85Gy EQD210、CTVHR D90% (EQD210)以及膀胱、直肠、乙状结肠和阴道5mm侧点剂量(EQD23)。
  • 采用多变量分析检验串联/卵形与串联/环形之间的差异。

主要发现

  • 在相似A点剂量下,环形-腔内中心较卵形-腔内中心平均CTVHR D90%高3.3 Gy,V85Gy低23%(中位靶区体积)。
  • 环形-腔内中心平均膀胱/直肠剂量(D2cm3和ICRU点)小3.2至7.7 Gy,阴道5mm侧点剂量高19.6 Gy。
  • 常规使用腔内/组织间插植技术使靶区剂量增加,V85Gy稳定(串联/环形)或降低(串联/卵形)。
  • 卵形中心常规使用腔内/组织间插植技术使膀胱和直肠D2cm3及膀胱ICRU点降低3.5至5.0 Gy,环形中心危及器官剂量相似。
  • 环形-腔内/组织间插植中心较卵形-腔内/组织间插植中心CTVHR D90%高2.8 Gy,膀胱D2cm3低4.3 Gy,直肠阴道ICRU点低4.8 Gy,阴道5mm侧点高22.4 Gy,所有比较P值<.002。

关键数值与推荐

  • 环形-腔内较卵形-腔内:CTVHR D90%高3.3 Gy,V85Gy低23%,膀胱/直肠剂量小3.2至7.7 Gy,阴道5mm侧点高19.6 Gy。
  • 环形-腔内/组织间插植较卵形-腔内/组织间插植:CTVHR D90%高2.8 Gy,膀胱D2cm3低4.3 Gy,直肠阴道ICRU点低4.8 Gy,阴道5mm侧点高22.4 Gy。
  • 所有上述比较P值<.002,多变量分析得出等效显著差异。

临床怎么用

  • 选择施用器和技术时应综合考虑靶区覆盖、危及器官剂量及阴道5mm侧点剂量。
  • 对于大靶区,腔内施用器覆盖不足,可考虑常规应用腔内/组织间插植技术以改善剂量。
  • 环形施用器在靶区剂量和膀胱直肠保护方面可能更有利,但需关注阴道5mm侧点剂量较高。
  • 技术/施用器选择还应结合实际操作考虑和临床结局。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate the influence of brachytherapy technique and applicator type on target dose, isodose surface volumes, and organ-at-risk (OAR) dose. METHODS AND MATERIALS: Nine hundred two patients treated with tandem/ovoids (T&O) (n = 299) and tandem/ring (T&R) (n = 603) applicators from 16 EMBRACE centers were analyzed. Patients received external beam radiation therapy and magnetic resonance imaging guided brachytherapy with dose prescription according to departmental practice. Centers were divided into 4 groups, according to applicator/technique: Ovoids and ring centers treating mainly with the intracavitary (IC) technique and ovoids and ring centers treating routinely with the intracavitary/interstitial (IC/IS) technique. V85Gy EQD210, CTVHR D90% (EQD210), and bladder, rectum, sigmoid, and vaginal 5-mm lateral-point doses (EQD23) were evaluated among center groups. Differences between T&O and T&R were tested with multivariable analysis. RESULTS: For similar point A doses, mean CTVHR D90% was 3.3 Gy higher and V85Gy was 23% lower for ring-IC compared with ovoids-IC centers (at median target volumes). Mean bladder/rectum doses (D2cm3 and ICRU-point) were 3.2 to 7.7 Gy smaller and vaginal 5-mm lateral-point was 19.6 Gy higher for ring-IC centers. Routine use of IC/IS technique resulted in increased target dose, whereas V85Gy was stable (T&R) or decreased (T&O); reduced bladder and rectum D2cm3 and bladder ICRU-point by 3.5 to 5.0 Gy for ovoids centers; and similar OAR doses for ring centers. CTVHR D90% was 2.8 Gy higher, bladder D2cm3 4.3 Gy lower, rectovaginal ICRU-point 4.8 Gy lower, and vagina 5-mm lateral-point 22.4 Gy higher for ring-IC/IS versus ovoids-IC/IS centers. The P values were <.002 for all comparisons. Equivalently, significant differences were derived from the multivariable analysis. CONCLUSIONS: T&R-IC applicators have better target dose and dose conformity than T&O-IC in this representative patient cohort. IC applicators fail to cover large target volumes, whereas routine application of IC/IS improves target and OAR dose considerably. Patients treated with T&R show a more favorable therapeutic ratio when evaluating target, bladder/rectum doses, and V85Gy. A comprehensive view on technique/applicators should furthermore include practical considerations and clinical outcome.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Serban M, Kirisits C, de Leeuw A, et al. Ring Versus Ovoids and Intracavitary Versus Intracavitary-Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 32007365. doi:10.1016/j.ijrobp.2019.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。